| 货号 | 19396-1mg |
| 描述 | LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM.1Inin vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively).2 LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.3,4 |
| 别名 | DM-3189; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Cuny, G.D.,Yu, P.B.,Laha, J.K., et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorganic & Medicinal Chemistry Letters 18(15), 4388-4392 (2008). 2.Sanvitale, C.E.,Kerr, G.,Chaikuad, A., et al. A new class of small molecule inhibitor of BMP signaling. PLoS One 8(4), 62721 (2013). 3.Yu, P.B.,Deng, D.Y.,Lai, C.S., et al. BMP type I receptor inhibition reduces heterotopic ossification. Nature Medicine 14(12), 1363-1369 (2008). 4.Lee, Y.C.,Cheng, C.J.,Bilen, M.A., et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Research 71(15), 5194-5203 (2011). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 443 |
| 分子式 | C25H22N6 • HCl |
| CAS号 | 1062368-62-0 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |